

## **Supplementary figure 6**



## **Supplementary figure 6**



Supplementary figure 6. Targeting of allogeneic immune cells by B7H3.CAR EBVSTs. A, B7-H3 expression on T, B, NK cells and monocytes after stimulation with various concentrations of GM-CSF, IFN-y and TNF- $\alpha$  for 2 days. **B,** Percentages of T, B and NK cells expressing B7-H3 after stimulation with 60 pg/mL IL-7 and 30 pg/mL 1L-15 for 1 or 2 days. C, Experiment set up to evaluate cytotoxicity of B7H3.CAR EBVSTs against cytokinestreated allogeneic PBMCs. D, B7-H3 expression on cytokine-treated allogeneic T, B and NK cells from 3 independent after co-culture with EBVSTs from 3 other donors. E, Median fluorescence intensities (MFI) of B7-H3 on allogeneic monocytes from 3 independent donors after co-culture with EBVSTs from 3 other donors. F, Experiment set up to evaluate B7-H3 expression on antigen-stimulated memory T cells. **G,** Expression of TNF- $\alpha$  and/or IFNy on EBVSTs (left) and CellTrace Violet™ dilution in proliferating cells (right) in response to control or EBV pepmix treatment. H, Comparison of B7-H3 expression on NCI-N87 cells and HSPC populations stimulated with Flt3L, TPO and SCF for the indicated number of days. I, Cytolysis of Flt3L, TPO and SCF-stimulated HSPC populations following co-culture with UT, B7H3.CAR EBVSTs or no effector cells. J, Experimental set up to evaluate effect of B7H3.CAR EBVSTs exposure on the erythroid and myeloid development potential of HSPCs. MPP: multi-potent progenitors, EMP: erythro-myeloid primed progenitors. LMPP: lymphoid-myeloid primed progenitors. MLP: multi-lymphoid primed progenitors. GMP: granulocyte and macrophage primed progenitors. Data in (A-B) is compiled from PBMCs from 3 donors. Data in (H and I) is compiled from UT and B7H3.CAR EBVSTs generated from 3 donors co-cultured with HSPCs isolated from 2 other different donors.